Merck CFO Caroline Litchfield said on the company’s earnings call Thursday that the drugmaker continues to expect strong growth from Keytruda. But she noted that the pricing of Keytruda “is an increasing headwind,” particularly as Merck launches new indications of the drug in key European marke...
Merck has shipped 6.4 million courses of molnupiravir around the world, distributing it to roughly 500,000 patients so far, CFO Caroline Litchfield told analysts during the company’s earnings call Thursday morning. Though the U.S. has ordered 3.1 million molnupiravir courses, the FDA gave a...
Next: Our Q1 2024 earnings report Innovation Celebrating the opening of our latest state-of-the-art facility The FLEx Center will help us continue to harness the power of leading-edge science with agility Read more Next: Celebrating the opening of our latest state-of-the-art facility In...
Next: Our Q1 2024 earnings report Innovation Celebrating the opening of our latest state-of-the-art facility The FLEx Center will help us continue to harness the power of leading-edge science with agility Read more Next: Celebrating the opening of our latest state-of-the-art facility In...
Merck KGaA (MKGAF) Q3 2024 Earnings Call TranscriptSA TranscriptsThu, Nov. 14 Merck KGaA (MKGAF) Q2 2024 Earnings Call TranscriptSA TranscriptsSat, Aug. 03 Merck KGaA (MKGAF) Q1 2024 Earnings Call TranscriptSA TranscriptsWed, May 15 Merck KGaA (MKGAF) Q4 2023 Earnings Call TranscriptSA Tr...
Q3 2024 Merck KGaA Earnings Call Transcript Nov. 15, 2024 at 12:14 a.m. ETon GuruFocus.com Merck KGaA Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science,...
Merck KGaA (OTCPK:MKGAF) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ETCompany ParticipantsConstantin Fest - Head of Investor RelationsBelén...
Merck accelerated its growth in the third quarter of 2024. All three business sectors achieved organic increases in sales and earnings.Share 3rd Quarter at glance Report & Documents Conference Calls Related News Key facts and Forecast Financial results of Q3 2024 Net sales up organically by 3.8%...
Glaxo, for its part, isn’t denying the fact that HIV is a competitive landscape. On April’s Q1 conference call, ViiV Chairman David Redfernacknowledgedto investors that with HIV now bringing in the bulk of Gilead’s growth, there’s “no doubt—the competitive intensity is not going down...
The maker of vaccines and diabetes drug Januvia reported net income of $736 million, or 27 cents per share, down 53 percent from $1.55 billion, or 56 cents per share, a year earlier. Earnings, adjusted for one-time costs, came to $1.05 per share, 6 cents better than Wall Street analy...